P01-114

A RANDOMIZED AND DOUBLE- BLIND CLINICAL TRIAL OF VENLAFAXINE HYDROCHLORIDE SUSTAINED RELEASE CAPSULES FOR TREATING JUVENILE DEPRESSION

C. Hongfen¹, J. Weidong¹, Z. Guoquan¹, Y. Chuang², G. Tianyou³

¹Psychiatry, Shanghai Changning Mental Health Center/Bio-X Center Hospital of Shanghai Jiaotong University, Shanghai,

²Psychiatry, Wenzhou Medical Collage, Wenzhou, ³Psychology, Shenzhen University, Shenzhen, China

Object: To evaluate the efficacy and safety of venlafaxine hydrochloride(HCL) sustained release capsules in treating juvenile with depressive disorder.

Methods: A randomized, double blind dummy clinical trial enrolled 60 adolescent patients with depression, who were randomizedly designed to administer venlafaxine HCL sustained release capsules 150 mg or fluoxetine 20 mg daily for 8 weeks. The efficacies of both treatment groups was evaluated based on the Hamilton Depression Scale and Clinical General impression Scale pre and post-treatment.

Results: The scores of Hamilton Depression Scale at the end of therapy were significantly reduced compared with the baseline in both gtnups ($P < 0.01$). The effective rate of venlafaxine HCL sustained release capsules versus fluoxetine treatmlent was 70.0% and 65.5%, respectively, the P value showed no statistical difference ($P > 0.05$). The common adverse reactions included dry mouth, insomnia, dizziness, and loss of appetite.

Conclusion: Venlafaxine HCl sustained release capsules is an effective agent for juvenile with major depression.